Table 2.

Network meta-analyses for OS.

Atezolizumab + Bevacizumab
0.62 (0.44, 0.88)	Brivanib
0.70 (0.49, 1.00)	1.13 (0.90, 1.4)	Donafenib
0.62 (0.43, 0.90)	1.00 (0.80, 1.25)	0.89 (0.7, 1.14)	Erlotinib + Sorafenib
0.63 (0.44, 0.89)	1.02 (0.83, 1.24)	0.90 (0.72, 1.13)	1.01 (0.80, 1.27)	Lenvatinib
0.55 (0.39, 0.79)	0.89 (0.73, 1.09)	0.79 (0.63, 1.00)	0.89 (0.70, 1.12)	0.88 (0.71, 1.08)	Linifanib
0.68 (0.48, 0.98)	1.10 (0.88, 1.37)	0.98 (0.76, 1.25)	1.09 (0.85, 1.40)	1.08 (0.86, 1.36)	1.24 (0.98, 1.56)	Nivolumab
0.37 (0.26, 0.54)	0.60 (0.48, 0.76)	0.54 (0.41, 0.69)	0.60 (0.46, 0.78)	0.59 (0.47, 0.75)	0.68 (0.53, 0.86)	0.55 (0.43, 0.71)	Placebo
0.59 (0.37, 0.96)	0.95 (0.65, 1.41)	0.85 (0.56, 1.27)	0.95 (0.63, 1.42)	0.94 (0.63, 1.39)	1.07 (0.72, 1.59)	0.87 (0.58, 1.30)	1.58 (1.05, 2.38)	Resminostat + Sorafenib
1.02 (0.67, 1.55)	1.64 (1.20, 2.23)	1.46 (1.05, 2.02)	1.63 (1.17, 2.27)	1.61 (1.18, 2.21)	1.84 (1.34, 2.53)	1.49 (1.07, 2.07)	2.77 (1.94, 3.78)	1.72 (1.09, 2.72)	Sintilimab +Bevacizumab
0.58 (0.42, 0.80)	0.93 (0.82, 1.07)	0.83 (0.70, 0.99)	0.93 (0.78, 1.11)	0.92 (0.79, 1.07)	1.05 (0.90, 1.22)	0.85 (0.71, 1.01)	1.55 (1.29, 1.87)	0.98 (0.68, 1.41)	0.57 (0.43, 0.75)	Sorafenib
0.55 (0.37, 0.82)	0.89 (0.68, 1.16)	0.79 (0.59, 1.05)	0.89 (0.66, 1.18)	0.88 (0.67, 1.15)	1.00 (0.76, 1.32)	0.81 (0.61, 1.08)	1.47 (1.10, 1.98)	0.93 (0.61, 1.43)	0.54 (0.38, 0.78)	0.95 (0.76, 1.20)	Sorafenib +Doxorubicin
0.45 (0.32, 0.63)	0.72 (0.59, 0.87)	0.64 (0.51, 0.80)	0.72 (0.57, 0.90)	0.71 (0.58, 0.87)	0.81 (0.66, 0.99)	0.65 (0.52, 0.82)	1.19 (0.94, 1.50)	0.75 (0.51, 1.12)	0.44 (0.32, 0.60)	0.77 (0.67, 0.89)	0.81 (0.62, 1.06)	Sunitinib
0.56 (0.35, 0.90)	0.91 (0.62, 1.32)	0.81 (0.54, 1.20)	0.90 (0.61, 1.34)	0.89 (0.61, 1.31)	1.02 (0.69, 1.50)	0.83 (0.56, 1.22)	1.50 (1.01, 2.24)	0.95 (0.57, 1.58)	0.55 (0.35, 0.87)	0.97 (0.68, 1.38)	1.02 (0.67, 1.56)	1.26 (0.86, 1.85)	Tigatuzumab + Sorafenib

OS, overall survival.